Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lilly

How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher

ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.

Investors Business Daily

Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test

Eli Lilly stock popped Wednesday after the company's weight-loss drug significantly reduced nighttime sleep apnea events.

Investors Business Daily

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

IBD Stock Of The Day Eli Lilly Jumps Early Entry As Viking Charges Obesity Space

Eli Lilly stock is Wednesday's IBD Stock Of The Day. Shares are forming a flat base as competition mounts for its weight-loss drug, Zepbound.

Investors Business Daily

Medicare Will Cover Weight-Loss Drugs — For Some. Here's What It Means For Novo, Lilly.

Novo Nordisk and Eli Lilly stocks dipped Thursday after Medicare said it could pay for weight-loss drugs for some members.

Investors Business Daily

Eli Lilly Taps Amazon's Pharmacy To Deliver Meds, Including Weight-Loss Drug Zepbound

Eli Lilly said Wednesday it tapped Amazon.com's pharmacy division to deliver some of its prescription meds, including its weight-loss drug.

Investors Business Daily

Novo Nordisk Wins FDA Approval For Obesity Drug, Wegovy, To Cut Cardiovascular Risk

Novo Nordisk said Friday its weight-loss drug gained FDA approval to cut the risk of heart attack and strokes. Novo Nordisk stock dipped.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Highly Awaited Alzheimer's Drug Hit By Delays

Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.

International Business Times

Biogen Surges On A Setback For Eli Lilly's Rival Alzheimer's Treatment

Biogen stock jumped Friday after the FDA delayed its approval decision on Eli Lilly's rival Alzheimer's treatment, donanemab.

Investors Business Daily

‘It feels like we’ve been lobotomised’: the possible sexual consequences of SSRIs

Long-term sexual dysfunction is a side-effect for some patients who take these widely prescribed antidepressants, and can leave sufferers devastated

The Guardian - UK

How The Red-Hot Obesity Space Could Help Eli Lilly Join The 1,000 Club

Lilly's new weight-loss drug could top $62 billion in 2030 sales, an analyst said Friday as he boosted his price target on Eli Lilly stock to 1,000.

Investors Business Daily

3 Biotech Stocks Climbing the Ranks to Watch

The biotech industry is thriving on growing applications across sectors from healthcare to agriculture, favorable government funding and policies, and technological breakthroughs. Amid this backdrop, quality biotech stocks UroGen Pharma (URGN), Foghorn Therapeutics (FHTX), and Galapagos (GLPG) might be ideal additions to one’s watchlist. Read on….

StockNews.com

2 Obesity Treatment Stocks Morgan Stanley Likes More than Novo Nordisk

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

Barchart

Viking Therapeutics Catapults 121% As Weight-Loss Drug Beats Out Lilly's Zepbound

A weight-loss drug from Viking topped Lilly's Zepbound in a midstage study Tuesday. Viking stock more than doubled, while Lilly shares fell.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Weight-Loss Tizzy: Why Altimmune Surged 23% As Others Tumbled On A New Study

Biotech stocks Madrigal and Altimmune diverged Monday as Wall Street debated the outcome of a weight-loss study in MASH patients.

Investors Business Daily

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Investors Business Daily

Will Weight-Loss, Diabetes Drugs Drive LLY Stock Into $1 Trillion Club?

Eli Lilly's weight-loss and diabetes drugs Zepbound and Mounjaro should drive the biopharma stock much higher, said a Morgan Stanley analyst.

Barchart

It's Not Too Late to Buy Eli Lilly Stock. Here's Why.

J.P. Morgan thinks sales of weight-loss drugs could exceed $100 billion by 2030. That's good news for Eli Lilly, which is now the largest pharma company by market capitalization and the 9th-biggest S&P 500 stock. Here's why LLY stock looks poised to put on even more weight in the months…

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review

The stock market rally hit fresh highs, with the S&P 500 hit 5,000. Arm and Palantir skyrocketed, with several other AI plays running higher.

Investors Business Daily

Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug

Viking Therapeutics moved up its timeline for an Eli Lilly-rivaling obesity treatment on Thursday, leading VKTX stock to a record high.

Investors Business Daily

Why Lilly's New Weight-Loss Study Absolutely Crushed 89bio, Akero, Madrigal

Eli Lilly stock pulled back from bullish gains Tuesday despite strong weight-loss drug sales and a promising test in liver disease treatment.

Investors Business Daily

Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record

Amgen stock slumped Monday — as Eli Lilly stock hit a record high — after the company unveiled preclinical results for its weight-loss drug.

The Guardian - UK

Weight loss injection to be made available in UK within weeks

Mounjaro will come in a four-dose device known as a KwikPen for people with type 2 diabetes or obesity

Investors Business Daily

IBD Stock Of The Day Eli Lilly Is Back In A Buy Zone. And It's Not Related To Obesity.

Eli Lilly stock is Wednesday's IBD Stock Of The Day. Shares are rallying on a gene therapy that could restore hearing loss.

The Independent UK

$100 million gift from Lilly Endowment aims to shore up HBCU endowments

The United Negro College Fund announced a donation of $100 million from the Lilly Endowment, the single largest unrestricted gift to the organization since its founding 80 years ago

1 … 5 6 7 8

People

Margaret Kaczor Andrew

11 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.